|
Mountain View, Calif./ September 4, 2001 / - SurroMed, Inc. today
announced that Christopher Becker, Ph.D., has joined the company
as director of chemistry and mass spectrometry. Dr. Becker is
an internationally renowned expert in mass spectrometry of biomolecules
and will lead SurroMed's efforts in proteomics and orgeomics (the
study of low molecular weight organic compounds such as peptides,
lipids and sugars) for improved and enhanced drug discovery and
development.
Dr. Becker, 49, has worked in the field of mass spectrometry
for over 20 years, most recently as senior director of proteomic
technology at ThermoFinnigan Corp. Prior to that, Dr. Becker was
co-founder and chief technology officer of GeneTrace Systems.
He received his Ph.D. from the University of California at Berkeley
and did his postdoctoral training at Massachusetts Institute of
Technology. He is the author of over 100 peer-reviewed publications.
"Mass spectrometry is a definitive technique for the analysis
of trace organic compounds and the cornerstone of SurroMed's proteomic
and orgeomic technologies," said Gordon Ringold, Ph.D., SurroMed's
co-founder, chairman and chief executive officer. "Under
Chris' leadership we will further develop our mass spectrometry-based
technologies that are valuable to SurroMed's integrated set of
phenotyping technologies, enabling more precise diagnosis and
treatment of human disease."
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its
integrated phenotyping and biological marker discovery platform
to better understand the root causes of disease and the factors
underlying patient-to-patient variations in disease presentation,
progression and response to therapy. Discoveries arising from
its research will enable improved, cost-efficient discovery and
development of therapeutic and diagnostic products. SurroMed's
phenotyping and biological marker discovery platform incorporates
advanced proprietary technologies for profiling and analysis of
hundreds of immune cell populations, proteins and low-molecular-weight
organic compounds (such as sugars, peptides and lipids) in small
volumes of blood and/or other biological samples, while maintaining
complete patient confidentiality. By capturing and analyzing enormous
amounts of clinical and biological information in a massively
parallel fashion to identify useful biological markers, SurroMed
plans to enable the precise diagnosis and effective treatment
of disease.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Executive
(415) 677-4455 ext.284
email: [email protected]
|
